Standard Radiation Therapy or Intensity-Modulated Pelvic Radiation Therapy in Treating Patients with Endometrial or Cervical Cancer

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Basic Trial Information

PhaseTypeAgeTrial IDs
Phase IIIBiomarker/Laboratory analysis, Supportive care, Treatment18 and overRTOG 1203
NCI-2012-02001, CDR0000738944, NCT01672892

Trial Description

Summary

This randomized phase III trial studies the side effects of intensity-modulated pelvic radiation and to see how well it works compared with standard radiation therapy in treating patients with endometrial or cervical cancer after surgery. Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. It is not yet known whether intensity-modulated pelvic radiation is more effective than standard radiation therapy in treating patients with endometrial or cervical cancer after surgery.

Further Study Information

PRIMARY OBJECTIVES:

I. To determine if intensity-modulated radiation therapy (IMRT) reduces acute gastrointestinal toxicity in the 5th week (after 23-25 fractions) of pelvic radiation as measured with Expanded Prostate Cancer Index Composite (EPIC).

SECONDARY OBJECTIVES:

I. To determine if grade 2 + gastrointestinal toxicity (Common Terminology Criteria for Adverse Events [CTCAE] version [v.] 4.0) is reduced with IMRT compared to conventional whole pelvic radiotherapy (WPRT).

II. To determine if grade 2+ hematologic toxicity (CTCAE v. 4.0) is reduced with IMRT compared to conventional WPRT.

III. To determine if urinary toxicity is reduced with IMRT using the EPIC urinary domain.

IV. To validate EPIC bowel and urinary domains in women undergoing either IMRT pelvic radiation treatment or four field pelvic radiation treatment for endometrial or cervical cancer.

V. To assess the impact of pelvic IMRT on quality of life using the Functional Assessment of Cancer Therapy-General (FACT-G) with cervix subscale.

VI. To determine if there is any difference in local-regional control, disease-free survival, and overall survival with IMRT as compared to conventional pelvic radiation therapy (RT).

VII. To perform a health utilities analysis to measure the financial impact of pelvic IMRT.

VIII. To identify molecular predictors of radiation toxicity and novel circulating cancer biomarkers.

IX. To determine if there is any difference in rate of secondary cancers with IMRT as compared to conventional pelvic RT.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients undergo standard (3-dimensional [3D]) radiation therapy once daily (QD), 5 days a week, for 5-6 weeks.

ARM II: Patients undergo IMRT QD, 5 days a week, for 5-6 weeks.

Some patients receive cisplatin intravenously (IV) over 1 hour on day 1. Treatment repeats every week for 5 weeks in the absence of unacceptable toxicity or disease progression.

After completion of study therapy, patients are followed up at 4-6 weeks, then every 6 months for 2 years, and then annually for 8 years.

Eligibility Criteria

Inclusion Criteria:

Appropriate stage for protocol entry, including no distant metastases, based upon the following minimum diagnostic workup:

History/physical examination within 45 days prior to registration

Computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET)-CT including the abdomen and pelvis should be performed for initial radiological staging; this may be performed pre- or post-surgery within 90 days prior to registration; imaging performed post-operatively should show no evidence of residual disease; any evidence of malignancy identified on pre-operative imaging should have been completely resected surgically prior to protocol treatment; chest CT or chest x-ray must be performed within 90 days prior to registration (unless a PET-CT has been performed)

Cervical cancer:

Patients with the following pathology findings may be treated with pelvic radiation with or without weekly cisplatin at the treating physician’s discretion; the decision to add weekly cisplatin for these patients is at the treating physician’s discretion

  • Patients with intermediate-risk features including two of the following histologic findings after radical hysterectomy:

*** 1/3 or more stromal invasion

*** Lymph-vascular space invasion

*** Large clinical tumor diameter (> 4 cm)

  • Patients with cervical cancer treated with a simple hysterectomy with negative margins

Patients with any of the following criteria following radical hysterectomy are eligible for this study and must receive weekly cisplatin:

  • Positive resected pelvic nodes and para-aortic nodes negative if removed: Note: if para-aortic nodes are not removed, CT abdomen or PET CT must demonstrate no evidence of lymphadenopathy
  • Microscopic parametrial invasion with negative margins

Endometrial cancer:

Patients with the following histologic features are eligible for pelvic radiation therapy without weekly cisplatin:

  • < 50% myometrial invasion, grade 3 adenocarcinoma without uterine serous carcinoma (USC) or clear cell histology
  • >= 50% myometrial invasion, grade 1-2 adenocarcinoma without USC or clear cell histology

Patients with the following histologic features may be treated with pelvic radiation with or without weekly cisplatin; the decision to add weekly cisplatin for these patients is at the treating physician’s discretion:

  • >= 50% myometrial invasion, grade 3 including USC and clear cell carcinoma
  • International Federation of Gynecology and Obstetrics (FIGO) 2009 stage II endometrial cancer of any grade including USC and clear cell carcinoma
  • FIGO 2009 stage IIIC1 (pelvic lymph node positive only, para-aortic nodes sampled and negative if removed) including USC and clear cell carcinoma; Note: if para-aortic nodes are not removed, CT abdomen or PET CT must demonstrate no evidence of lymphadenopathy

For patients receiving chemotherapy:

Within 14 days prior to registration, serum creatinine =< 1.5 mg/dL and calculated creatinine clearance >= 50 cc/min; both tests must be within these limits; the creatinine clearance should be calculated using the Cockcroft-Gault formula

Aspartate aminotransferase (AST) =< 2 times upper limit of normal (ULN)

Bilirubin =< 2 times ULN

Alkaline phosphatase, magnesium, blood urea nitrogen (BUN), and electrolytes must be obtained and recorded

Pathologically proven diagnosis of endometrial or cervical cancer

Zubrod performance status 0-2

Platelets >= 100,000 cells/mm^3

Willingness and ability to complete the bowel and urinary domains of the EPIC prior to registration

Patients must have undergone a hysterectomy (total abdominal hysterectomy, vaginal hysterectomy or radical hysterectomy, or total laparoscopic hysterectomy) for carcinoma of the cervix or endometrium within 49 days prior to registration; performance of a bilateral salpingo-oophorectomy will be at the treating surgeon’s discretion

Patient must provide study specific informed consent prior to study entry

Absolute neutrophil count (ANC) >= 1,500 cells/mm^3

Hemoglobin (Hgb) >= 8.0 g/dL (Note: the use of transfusion or other intervention to achieve Hgb >= 8.0 g/dL is acceptable)

Exclusion Criteria:

Prior invasive malignancy (except non-melanomatous skin cancer) unless disease-free for a minimum of 3 years

Severe, active co-morbidity, defined as follows:

Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months

Transmural myocardial infarction within the last 6 months

Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration

Other major medical illness that requires hospitalization or precludes study therapy at the time of registration

Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory test coagulation parameters are not required for entry into this protocol

Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control (CDC) definition; not, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol; protocol-specific requirements may also exclude immunocompromised patients

Patients with histology consisting of endometrial stromal sarcoma, leiomyosarcoma or malignant mixed Mullerian tumor (MMMT or carcinosarcoma)

Patients with para-aortic nodal disease or who require extended field radiotherapy beyond the pelvis

Patients who exceed the weight/size limits of the treatment table or CT scanner

Mental status changes or bladder control problems that make the patient unable to comply with bladder-filling instructions

Prior radiation therapy to the pelvis

Patients with active inflammatory bowel disease

Patients with prior treatment with platinum-based chemotherapy

Patients with evidence of metastatic disease outside of the pelvis

Patients with positive or close (< 3 mm) resection margins

Women who are breastfeeding

Trial Contact Information

Trial Lead Organizations / Sponsors / Collaborators

NRG Oncology

  • National Cancer Institute
Ann H. Klopp, Principal Investigator

Trial Sites

U.S.A.

Arizona
Scottsdale

Arizona Oncology Services Foundation

David G. Brachman
Ph: 877-602-4111

David G. Brachman
Principal Investigator

California
Oakland

Kaiser Permanente Oakland-Broadway

Samantha Andrews Seaward
Ph: 626-564-3455

Samantha Andrews Seaward
Principal Investigator

Orange

Saint Joseph Hospital - Orange

Venita Lai Williams
Ph: 714-734-6220

Venita Lai Williams
Principal Investigator

Paradise

Feather River Cancer Center

Sam Mazj
Ph: 530-876-7995
Email: haleew@ah.org

Sam Mazj
Principal Investigator

Pomona

Pomona Valley Hospital Medical Center

Yallapragada S. (Ram) Rao
Ph: 909-865-9555

Yallapragada S. (Ram) Rao
Principal Investigator

Rancho Cardova

Kaiser Permanente-Rancho Cordova Cancer Center

Samantha Andrews Seaward
Ph: 626-564-3455

Samantha Andrews Seaward
Principal Investigator

Rohnert Park

Rohnert Park Cancer Center

Samantha Andrews Seaward
Ph: 626-564-3455

Samantha Andrews Seaward
Principal Investigator

Roseville

The Permanente Medical Group-Roseville Radiation Oncology

Samantha Andrews Seaward
Ph: 626-564-3455

Samantha Andrews Seaward
Principal Investigator

Sacramento

South Sacramento Cancer Center

Samantha Andrews Seaward
Ph: 626-564-3455

Samantha Andrews Seaward
Principal Investigator

Santa Clara

Kaiser Permanente Medical Center - Santa Clara

Samantha Andrews Seaward
Ph: 626-564-3455

Samantha Andrews Seaward
Principal Investigator

South San Francisco

Kaiser Permanente Cancer Treatment Center

Samantha Andrews Seaward
Ph: 626-564-3455

Samantha Andrews Seaward
Principal Investigator

Colorado
Aurora

University of Colorado Cancer Center - Anschutz Cancer Pavilion

Christine Megan Fisher
Ph: 720-848-0650

Christine Megan Fisher
Principal Investigator

Colorado Springs

Penrose-Saint Francis Healthcare

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Denver

Porter Adventist Hospital

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Englewood

Swedish Medical Center

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Littleton

Rocky Mountain Cancer Centers-Littleton

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Longmont

Longmont United Hospital

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Loveland

McKee Medical Center

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Parker

Parker Adventist Hospital

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Delaware
Newark

Christiana Care Health System-Christiana Hospital

Adam Raben
Ph: 302-733-6227

Adam Raben
Principal Investigator

Rehoboth Beach

Beebe Health Campus

Adam Raben
Ph: 302-733-6227

Adam Raben
Principal Investigator

District of Columbia
Washington

Washington Hospital Center

Adedamola (Mola) B. Omogbehin
Ph: 202-877-8839

Adedamola (Mola) B. Omogbehin
Principal Investigator

Georgia
Atlanta

Emory University/Winship Cancer Institute

Joseph William Shelton
Ph: 404-489-9164

Joseph William Shelton
Principal Investigator

Joseph William Shelton
Ph: 404-489-9164

Joseph William Shelton
Principal Investigator

Grady Health System

Joseph William Shelton
Ph: 404-489-9164

Joseph William Shelton
Principal Investigator

Piedmont Hospital

Adam Wayne Nowlan
Ph: 404-425-7943
Email: ORS@piedmont.org

Adam Wayne Nowlan
Principal Investigator

Savannah

Lewis Cancer and Research Pavilion at Saint Joseph's/Candler

John A. Pablo
Ph: 800-622-6877

John A. Pablo
Principal Investigator

Hawaii
Ewa Beach

The Cancer Center of Hawaii-Leeward

Paul Arthur DeMare
Ph: 808-545-8548

Paul Arthur DeMare
Principal Investigator

Honolulu

Queen's Medical Center

Paul Arthur DeMare
Ph: 808-545-8548

Paul Arthur DeMare
Principal Investigator

The Cancer Center of Hawaii-Liliha

Paul Arthur DeMare
Ph: 808-545-8548

Paul Arthur DeMare
Principal Investigator

University of Hawaii Cancer Center

Paul Arthur DeMare
Ph: 808-545-8548

Paul Arthur DeMare
Principal Investigator

Idaho
Boise

Saint Alphonsus Cancer Care Center-Boise

Samir Narayan
Ph: 734-712-4673

Samir Narayan
Principal Investigator

Illinois
Chicago

Advocate Illinois Masonic Medical Center

Paige L. Dorn
Ph: 773-296-5360

Paige L. Dorn
Principal Investigator

John H Stroger Jr Hospital of Cook County

Anupama Thakrar
Ph: 312-864-6000

Anupama Thakrar
Principal Investigator

Saint Joseph Hospital

Nicholas S. Galanopoulos
Ph: 773-665-3109

Nicholas S. Galanopoulos
Principal Investigator

Harvey

Ingalls Memorial Hospital

Sulochana D. Yalavarthi
Ph: 708-915-4673
Email: clinicaltrials@ingalls.org

Sulochana D. Yalavarthi
Principal Investigator

Maywood

Loyola University Medical Center

Matthew M. Harkenrider
Ph: 708-226-4357

Matthew M. Harkenrider
Principal Investigator

Peoria

OSF Saint Francis Medical Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Springfield

Saint John's Hospital

Laurent Brard
Ph: 217-525-5666
Email: diana.weyhenmeyer@st-johns.org

Laurent Brard
Principal Investigator

Warrenville

Cadence Cancer Center in Warrenville

LaToya J. Perry
Ph: 630-208-4563
Email: kevin.tomczyk@delnor.com

LaToya J. Perry
Principal Investigator

Indiana
Anderson

Saint Vincent Anderson Regional Hospital/Cancer Center

Maria J. Valente
Ph: 904-538-3667

Maria J. Valente
Principal Investigator

Fort Wayne

Parkview Hospital Randallia

Brian K. Chang
Ph: 260-373-8888
Email: parkviewresearch@parkview.com

Brian K. Chang
Principal Investigator

Radiation Oncology Associates PC

Brian K. Chang
Ph: 260-373-8888
Email: parkviewresearch@parkview.com

Brian K. Chang
Principal Investigator

Iowa
Ames

McFarland Clinic PC-William R Bliss Cancer Center

Joseph James Merchant
Ph: 515-239-2621

Joseph James Merchant
Principal Investigator

Des Moines

Iowa Methodist Medical Center

Robert J. Behrens
Ph: 515-282-2921

Robert J. Behrens
Principal Investigator

Louisiana
New Orleans

Ochsner Medical Center Jefferson

Mini J. Elnaggar
Ph: 888-562-4763

Mini J. Elnaggar
Principal Investigator

Maryland
Baltimore

Greater Baltimore Medical Center

Geoffrey Alexander Neuner
Ph: 443-849-3706

Geoffrey Alexander Neuner
Principal Investigator

Sinai Hospital of Baltimore

Jeanette A.F. Linder
Ph: 410-601-6120
Email: pridgely@lifebridgehealth.org

Jeanette A.F. Linder
Principal Investigator

Salisbury

Peninsula Regional Medical Center

Matthew L. Snyder
Ph: 866-922-6237

Matthew L. Snyder
Principal Investigator

Massachusetts
Boston

Brigham and Women's Hospital

Akila N. Viswanathan
Ph: 617-724-5200

Akila N. Viswanathan
Principal Investigator

Dana-Farber Cancer Institute

Akila N. Viswanathan
Ph: 617-724-5200

Akila N. Viswanathan
Principal Investigator

Lowell

Lowell General Hospital

Akila N. Viswanathan
Ph: 617-724-5200

Akila N. Viswanathan
Principal Investigator

Milford

Dana-Farber/Brigham and Women's Cancer Center at Milford Regional

Akila N. Viswanathan
Ph: 617-724-5200

Akila N. Viswanathan
Principal Investigator

South Weymouth

Dana-Farber/Brigham and Women's Cancer Center at South Shore

Akila N. Viswanathan
Ph: 617-724-5200

Akila N. Viswanathan
Principal Investigator

Springfield

Baystate Medical Center

Seth A. Kaufman
Ph: 413-794-9338

Seth A. Kaufman
Principal Investigator

Michigan
Ann Arbor

Saint Joseph Mercy Hospital

Samir Narayan
Ph: 734-712-4673

Samir Narayan
Principal Investigator

Detroit

Saint John Hospital and Medical Center

Samir Narayan
Ph: 734-712-4673

Samir Narayan
Principal Investigator

Livonia

Saint Mary Mercy Hospital

Samir Narayan
Ph: 734-712-4673

Samir Narayan
Principal Investigator

Warren

Saint John Macomb-Oakland Hospital

Samir Narayan
Ph: 734-712-4673

Samir Narayan
Principal Investigator

Minnesota
Bemidji

Sanford Clinic North-Bemidgi

Preston D. Steen
Ph: 701-234-6161

Preston D. Steen
Principal Investigator

Saint Paul

United Hospital

Paul W. Sperduto
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Paul W. Sperduto
Principal Investigator

Waconia

Ridgeview Medical Center

Paul W. Sperduto
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Paul W. Sperduto
Principal Investigator

Missouri
Springfield

CoxHealth South Hospital

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Montana
Billings

Billings Clinic Cancer Center

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

New Hampshire
Lebanon

Dartmouth Hitchcock Medical Center

Leslie R. DeMars
Ph: 800-639-6918
Email: cancer.research.nurse@dartmouth.edu

Leslie R. DeMars
Principal Investigator

New Jersey
Camden

Cooper Hospital University Medical Center

Lesley Ann Hughes
Ph: 856-325-6757

Lesley Ann Hughes
Principal Investigator

Mount Holly

Fox Chase Cancer Center at Virtua Memorial Hospital of Burlington County

Lemuel S. Ariaratnam
Ph: 888-847-8823

Lemuel S. Ariaratnam
Principal Investigator

Pennington

Capital Health Medical Center-Hopewell

Shirnett Karean Williamson
Ph: 800-255-3440

Shirnett Karean Williamson
Principal Investigator

Voorhees

MD Anderson Cancer Center at Cooper-Voorhees

Lesley Ann Hughes
Ph: 856-325-6757

Lesley Ann Hughes
Principal Investigator

Virtua West Jersey Hospital Voorhees

Lemuel S. Ariaratnam
Ph: 888-847-8823

Lemuel S. Ariaratnam
Principal Investigator

New York
Bay Shore

Southside Hospital

Beatrice F. Bloom
Ph: 516-562-3467

Beatrice F. Bloom
Principal Investigator

Brooklyn

The New York Methodist Hospital

Katherine Economos
Ph: 718-780-5240

Katherine Economos
Principal Investigator

New Hyde Park

Long Island Jewish Medical Center

Beatrice F. Bloom
Ph: 516-562-3467

Beatrice F. Bloom
Principal Investigator

North Shore-LIJ Health System/Center for Advanced Medicine

Beatrice F. Bloom
Ph: 516-562-3467

Beatrice F. Bloom
Principal Investigator

North Carolina
Supply

South Atlantic Radiation Oncology

Michael A. Papagikos
Ph: 910-251-1839

Michael A. Papagikos
Principal Investigator

Wilmington

Coastal Carolina Radiation Oncology

Michael A. Papagikos
Ph: 910-251-1839

Michael A. Papagikos
Principal Investigator

New Hanover Regional Medical Center/Zimmer Cancer Center

Michael A. Papagikos
Ph: 910-251-1839

Michael A. Papagikos
Principal Investigator

North Dakota
Bismarck

Sanford Bismarck Medical Center

Preston D. Steen
Ph: 701-234-6161

Preston D. Steen
Principal Investigator

Fargo

Roger Maris Cancer Center

Preston D. Steen
Ph: 701-234-6161

Preston D. Steen
Principal Investigator

Grand Forks

Altru Cancer Center

Grant Richard Seeger
Ph: 701-780-6520

Grant Richard Seeger
Principal Investigator

Ohio
Akron

Akron General Medical Center

Mitchel L. Fromm
Ph: 330-344-6348

Mitchel L. Fromm
Principal Investigator

Summa Akron City Hospital/Cooper Cancer Center

Charles Andrew Kunos
Ph: 330-375-6101

Charles Andrew Kunos
Principal Investigator

Barberton

Summa Barberton Hospital

Charles Andrew Kunos
Ph: 330-375-6101

Charles Andrew Kunos
Principal Investigator

Beachwood

UHHS-Chagrin Highlands Medical Center

Tracy Sherertz
Ph: 800-641-2422

Tracy Sherertz
Principal Investigator

Chardon

Geaugra Hospital

Tracy Sherertz
Ph: 800-641-2422

Tracy Sherertz
Principal Investigator

Cincinnati

Good Samaritan Hospital - Cincinnati

James Clifford Pavelka
Ph: 513-862-2230

James Clifford Pavelka
Principal Investigator

Cleveland

Case Western Reserve University

Tracy Sherertz
Ph: 800-641-2422

Tracy Sherertz
Principal Investigator

Columbus

The Mark H Zangmeister Center

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

Medina

Summa Health Center at Lake Medina

Charles Andrew Kunos
Ph: 330-375-6101

Charles Andrew Kunos
Principal Investigator

Mentor

Lake University Ireland Cancer Center

Tracy Sherertz
Ph: 800-641-2422

Tracy Sherertz
Principal Investigator

Middleburg Heights

Southwest General Health Center Ireland Cancer Center

Tracy Sherertz
Ph: 800-641-2422

Tracy Sherertz
Principal Investigator

Portsmouth

Southern Ohio Medical Center

John Philip Kuebler
Ph: 800-446-5532

John Philip Kuebler
Principal Investigator

Ravenna

Robinson Radiation Oncology

Mitchel L. Fromm
Ph: 330-344-6348

Mitchel L. Fromm
Principal Investigator

Westlake

UHHS-Westlake Medical Center

Tracy Sherertz
Ph: 800-641-2422

Tracy Sherertz
Principal Investigator

Oklahoma
Oklahoma City

University of Oklahoma Health Sciences Center

Terence S. Herman
Ph: 405-271-4272
Email: julie-traylor@ouhsc.edu

Terence S. Herman
Principal Investigator

Pennsylvania
Abington

Abington Memorial Hospital

Wayne H. Pinover
Ph: 215-481-2402

Wayne H. Pinover
Principal Investigator

Danville

Geisinger Medical Center

Thomas James Gergel
Ph: 570-271-5251

Thomas James Gergel
Principal Investigator

Paoli

Paoli Memorial Hospital

Albert S. DeNittis
Ph: 866-225-5654

Albert S. DeNittis
Principal Investigator

West Reading

Reading Hospital

Albert Yuen
Ph: 610-988-9323

Albert Yuen
Principal Investigator

Wynnewood

Lankenau Medical Center

Albert S. DeNittis
Ph: 866-225-5654

Albert S. DeNittis
Principal Investigator

South Carolina
Greenville

Greenville Health System Cancer Institute-Eastside

David Lawrence Grisell
Ph: 864-241-6251

David Lawrence Grisell
Principal Investigator

Greenville Health System Cancer Institute-Faris

David Lawrence Grisell
Ph: 864-241-6251

David Lawrence Grisell
Principal Investigator

Greer

Greenville Health System Cancer Institute-Greer

David Lawrence Grisell
Ph: 864-241-6251

David Lawrence Grisell
Principal Investigator

Seneca

Greenville Health System Cancer Institute-Seneca

David Lawrence Grisell
Ph: 864-241-6251

David Lawrence Grisell
Principal Investigator

Spartanburg

Greenville Health System Cancer Institute-Spartanburg

David Lawrence Grisell
Ph: 864-241-6251

David Lawrence Grisell
Principal Investigator

South Dakota
Rapid City

Rapid City Regional Hospital

Michael J. Swartz
Ph: 605-716-3982
Email: research@rcrh.org

Michael J. Swartz
Principal Investigator

Sioux Falls

Avera Cancer Institute

Luis A. Rojas-Espaillat
Ph: 800-657-4377
Email: Jan.Healy@avera.org

Luis A. Rojas-Espaillat
Principal Investigator

Sanford USD Medical Center - Sioux Falls

Preston D. Steen
Ph: 701-234-6161

Preston D. Steen
Principal Investigator

Texas
Dallas

UT Southwestern/Simmons Cancer Center-Dallas

Kevin V. Albuquerque
Ph: 214-648-7097

Kevin V. Albuquerque
Principal Investigator

Utah
Logan

Logan Regional Hospital

R. Jeffrey Lee
Ph: 801-507-3950

R. Jeffrey Lee
Principal Investigator

Murray

Intermountain Medical Center

R. Jeffrey Lee
Ph: 801-507-3950

R. Jeffrey Lee
Principal Investigator

Saint George

Dixie Medical Center Regional Cancer Center

R. Jeffrey Lee
Ph: 801-507-3950

R. Jeffrey Lee
Principal Investigator

Salt Lake City

Huntsman Cancer Institute/University of Utah

David A. Bush
Ph: 909-558-3375

David A. Bush
Principal Investigator

LDS Hospital

R. Jeffrey Lee
Ph: 801-507-3950

R. Jeffrey Lee
Principal Investigator

Utah Cancer Specialists-Salt Lake City

R. Jeffrey Lee
Ph: 801-507-3950

R. Jeffrey Lee
Principal Investigator

Virginia
Charlottesville

University of Virginia Cancer Center

Timothy Norman Showalter
Ph: 434-243-6143

Timothy Norman Showalter
Principal Investigator

Richmond

Virginia Commonwealth University/Massey Cancer Center

Emma Charlotte Fields
Ph: 804-628-1939

Emma Charlotte Fields
Principal Investigator

Washington
Seattle

Virginia Mason CCOP

Huong Thanh Pham
Ph: 206-342-6954
Email: vmmc.cancer_clinical_research@VirginiaMason.org

Huong Thanh Pham
Principal Investigator

West Virginia
Wheeling

Wheeling Hospital/Schiffler Cancer Center

Jondavid Pollock
Ph: 304-243-6442

Jondavid Pollock
Principal Investigator

Wisconsin
Green Bay

Aurora BayCare Medical Center

Mitchell Hal Pincus
Ph: 800-252-2990

Mitchell Hal Pincus
Principal Investigator

Madison

University of Wisconsin Hospital and Clinics

Kristin A. Bradley
Ph: 877-405-6866

Kristin A. Bradley
Principal Investigator

Milwaukee

Aurora Saint Luke's Medical Center

Mitchell Hal Pincus
Ph: 800-252-2990

Mitchell Hal Pincus
Principal Investigator

Oshkosh

Vince Lombardi Cancer Clinic - Oshkosh

Mitchell Hal Pincus
Ph: 800-252-2990

Mitchell Hal Pincus
Principal Investigator

Summit

Aurora Medical Center in Summit

Mitchell Hal Pincus
Ph: 800-252-2990

Mitchell Hal Pincus
Principal Investigator

West Allis

Aurora West Allis Medical Center

Mitchell Hal Pincus
Ph: 800-252-2990

Mitchell Hal Pincus
Principal Investigator

Canada

British Columbia
Kelowna

BCCA-Cancer Centre for the Southern Interior

Francois Bachand
Ph: 250-712-3900

Francois Bachand
Principal Investigator

Victoria

BCCA-Vancouver Island Cancer Centre

Caroline Louise Holloway
Ph: 604-877-6010

Caroline Louise Holloway
Principal Investigator

Ontario
Windsor

Windsor Regional Cancer Centre

Kenneth Michael Schneider
Ph: 519-253-5253

Kenneth Michael Schneider
Principal Investigator

Hong Kong

Chai Wan

Pamela Youde Nethersole Eastern Hospital

Amy Tien Yee Chang
Ph: 888-823-5923
Email: ctsucontact@westat.com

Amy Tien Yee Chang
Principal Investigator

Israel

Tel Hashomer

Chaim Sheba Medical Center

Richard James (Yaacov) Lawrence
Ph: 972 3 530-5943

Richard James (Yaacov) Lawrence
Principal Investigator

Republic of Korea

Seoul

Yonsei University Health System-Severance Hospital

Yong Bae Kim
Ph: 888-823-5923
Email: ctsucontact@westat.com

Yong Bae Kim
Principal Investigator

Republic of Singapore

Singapore

National Cancer Centre

Francis Kuok Choon Chin
Ph: 65 6225 5655
Email: cancerhelpline@nccs.com.sg

Francis Kuok Choon Chin
Principal Investigator

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT01672892

Note: Information about participating sites on pharmaceutical industry trials may be incomplete. Please visit the ClinicalTrials.gov record via the link above for more information about participating sites.